Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

5 Defensive Stocks to Buy as Volatility Index Soars

On Dec 9, the fear gauge jumped 16% as uncertainties in the closure of U.S.-China trade deal instilled fear in investors. Here are five defensive stocks to shield your portfolio.

Globus Medical Hits 52-Week High: What's Driving the Stock?

Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.

Omnicell (OMCL) Partners With Kit Check to Offer Bluesight

This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.

Zacks.com featured highlights include: ResMed, Booz Allen Hamilton, United Technologies, McGrath RentCorp and SS&C Technologies

Zacks.com featured highlights include: ResMed, Booz Allen Hamilton, United Technologies, McGrath RentCorp and SS&C Technologies

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality

Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth

Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.

Amedisys (AMED) Benefits From Home Health and Personal Care

Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.

Thermo Fisher (TMO) at a 52-Week High: What's Driving It?

Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.

NuVasive Hits New 52-Week High: What's Driving the Stock?

NuVasive (NUVA) is optimistic about maintaining the momentum on several positive developments.

TransMedics' OCS Technology Sees Success in Heart Transplant

TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.

Sweta Killa headshot

5 Dividend Stocks That Possess Strong Growth Potential

Although the dividend growth stocks do not necessarily have the highest yields, they have outperformed for a longer period than the broader stock market or any other dividend-paying stock.

Omnicell to Feature Upgrades in Medication Management at ASHP

Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality

Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality

Patterson Companies (PDCO) Q2 Earnings Surpass Estimates

Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.

Myriad Genetics Reports Favorable Study Result on Prequel

Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.

Boston Scientific's Watchman Implant Study Results Encourage

These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.

NuVasive Advances on Global Footprint Despite Pricing Woes

Within NuVasive's (NUVA) U.S. Spinal Hardware business, a strong uptick in case volume and tangible growth in the XLIF and ALIF franchises are major upsides.

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits

Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.

4 GARP Stocks to Scoop Up for Maximum Returns

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

What's in the Cards for Cantel Medical (CMD) in Q1 Earnings?

Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.

Haemonetics (HAE) Launches SafeTrace Tx in North America

Haemonetics (HAE) expands the transfusion management portfolio with SafeTrace Tx, the latest in its transfusion management software product line.

Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries

The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.

The Zacks Analyst Blog Highlights: Walmart, NIKE, Citigroup, Intel and ResMed

The Zacks Analyst Blog Highlights: Walmart, NIKE, Citigroup, Intel and ResMed

RadNet Hits New 52-Week High: What's Driving the Stock?

RadNet (RDNT) is optimistic about maintaining momentum on several positive developments.

Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA

Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.